# **UNDERSTANDING THE DISEASE**



# Understanding hypoxemia on ECCO<sub>2</sub>R: back to the alveolar gas equation

Jean-Luc Diehl<sup>1,2\*</sup>, Alain Mercat<sup>3</sup> and Antonio Pesenti<sup>4,5</sup>

© 2018 Springer-Verlag GmbH Germany, part of Springer Nature and ESICM

Extracorporeal CO<sub>2</sub> removal (ECCO<sub>2</sub>R) is a promising technique for ARDS and for severe acute exacerbations of COPD [1]. However, ECCO<sub>2</sub>R carries its own risk of complications and side effects. Beyond hemorrhagic and thrombotic complications and hemolysis, the occurrence of progressive hypoxemia has been reported in COPD patients treated by ECCO<sub>2</sub>R, leading to a tracheal intubation rate of 28% in the prospective series from Braune et al. [2]. Obviously, progressive hypoxemia can be explained by pulmonary complications such as evolving infiltrates, even if other factors such as modification of the respiratory quotient have been proposed [2, 3]. Accordingly, we illustrate such a mechanism, intrinsically linked to the ECCO<sub>2</sub>R technique and not involving any worsening of lung function by itself.

A 76-year-old man was admitted because of a very severe hypercapnic acute exacerbation of a chronic respiratory failure due to non-cystic fibrosis bronchiectasis. Invasive mechanical ventilation (Carescape R860 GE Healthcare) was initiated because of non-invasive ventilation failure. ECCO<sub>2</sub>R was started 24 h later with the goals of limiting hypercapnia and dynamic hyperinflation and promoting a rapid weaning process [4]. The iLA-Activve system (Xenios-Novalung, Heilbronn) was used with a 22-Fr right jugular veno-venous catheter. Since weaning was a very difficult process, the sweep gas flow was progressively increased during the next 7 days from 1 to 9 L/min, while the extracorporeal blood flow varied between 0.8 and 1.2 L/min. During the same period, the PaO<sub>2</sub>/FiO<sub>2</sub> ratio progressively decreased from 251 to 145, with no obvious pulmonary complication. Table 1 indicates the corresponding ABG and PaO<sub>2</sub>/ FiO<sub>2</sub> values as well as the DA-aO<sub>2</sub> values calculated either using the classical simplified alveolar air equation, i.e.,  $PAO_2 = PIO_2 - PACO_2/0.8$ , or the exact simplified alveolar air equation using the 0.3 value of the respiratory quotient displayed by the ventilator. Despite the apparent changes in PaO<sub>2</sub>/FiO<sub>2</sub> ratio, the correct DA-aO<sub>2</sub> and PAO<sub>2</sub> were compatible with clinically negligible changes in intrapulmonary shunt, oscillating around 15%, even if we cannot totally exclude confounding factors inferring with the shunt calculation such as a higher mixed venous PO<sub>2</sub> (even if it is generally believed that ECCO<sub>2</sub>R exerts only minimal oxygenation effects), a release of hypoxic pulmonary vasoconstriction due to a higher FiO<sub>2</sub>, or a shunt decrease in relation to higher FiO2 as described in moderate ARDS. The observed changes in PaO<sub>2</sub>/FiO<sub>2</sub> were therefore mainly justified by changes in PAO<sub>2</sub> due to changes in the VCO<sub>2</sub>/VO<sub>2</sub> ratio of the patient's own lung, rather than to changes in its oxygenation function. Accordingly, no specific pulmonary complication was diagnosed during the following days.

ECCO $_2$ R exerts predominantly an effective extracorporeal CO $_2$  removal, without significant effect on oxygenation which accordingly occurs very predominantly in the native lungs, resulting in a decreased native lung respiratory quotient. It is therefore very important to use during ECCO $_2$ R the exact calculations of PaO $_2$  and Da-aO $_2$  when a suitable monitoring system is available, or at least to interpret with great caution any PaO $_2$ /FiO $_2$  worsening, which could, at least in part, reflect an ECCO $_2$ R-induced modification of the alveolar gas content [5].

Full author information is available at the end of the article



<sup>\*</sup>Correspondence: jean-luc.diehl@aphp.fr

<sup>&</sup>lt;sup>1</sup> Department of Intensive Care Medicine, Hôpital Européen Georges Pompidou, Paris, France

Table 1 Oxygenation values, ABG values, and invasive mechanical ventilation parameters recorded immediately before initiation of ECCO<sub>2</sub>R and under ECCO<sub>2</sub>R after raising the sweep gas flow to 9 L/min

	Immediately before ECCO <sub>2</sub> R	ECCO₂R day 7
PaO <sub>2</sub> /FiO <sub>2</sub>	251	145
PaO <sub>2</sub> (mmHg) simplified	186	360
PaO <sub>2</sub> (mmHg) exact	_	248
Da-aO <sub>2</sub> (mmHg) simplified	98	273
Da-aO <sub>2</sub> (mmHg) exact	_	161
R (native lungs) measured by the ventilator	-	0.3
рН	7.31	7.38
PaO <sub>2</sub> (mmHg)	88	87
PaCO <sub>2</sub> (mmHg)	51	54
Ventilatory mode	ACV	ACV
VT (mL/kg IBW)	6	6
RR (/min)	12	10
PEEP (cmH <sub>2</sub> O)	0	5
FiO <sub>2</sub>	0.35	0.6

A alveolar,  $DA-aO_2$  difference between alveolar and arterial  $O_2$  partial pressures, R respiratory quotient displayed by the ventilator, simplified assuming that R is equal to 0.8, exact using the measured value of R, ACV assist-controlled ventilation, VT tidal volume, RR respiratory rate

# **Author details**

<sup>1</sup> Department of Intensive Care Medicine, Hôpital Européen Georges Pompidou, Paris, France. <sup>2</sup> INSERM, UMR\_S1140: Innovations Thérapeutiques en Hémostase, Faculté des Sciences Pharmaceutiques et Biologiques, Paris Descartes University, Paris, France. <sup>3</sup> Département de Médecine Intensive-Réanimation et Médecine Hyperbare, Centre Hospitalier Universitaire d'Angers, Université d'Angers, Angers, France. <sup>4</sup> Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. <sup>5</sup> Department of Anesthesia, Critical Care and Emergency Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, Italy.

### **Funding information**

No specific funding has been dedicated to this publication.

## Compliance with ethical standards

## **Conflicts of interest**

Jean-Luc Diehl received fees from Xenios and Alung for consulting and lectures. Funding for research purposes: Alung Technologies (EPHEBE study, NCT02586948). Alain Mercat received fees from Alung for lectures. Antonio Pesenti received fees from Xenios and Getinge for consulting and lectures.

### **Fthical statement**

Treatment with ECCO $_2$ R was performed as part of a specific registry (Registry on the EXperience of Extracorporeal CO $_2$  Removal in Intensive Care Units, NCT02965079), benefiting from an approval (07 March 2016) from the Ethics Committee of the French Intensive Care Society.

Received: 12 September 2018 Accepted: 6 October 2018 Published online: 15 October 2018

### References

- Morelli A, Del Sorbo L, Pesenti A, Ranieri VM, Fan E (2017) Extracorporeal carbon dioxide removal (ECCO2R) in patients with acute respiratory failure. Intensive Care Med 43(4):519–530
- Braune S, Sieweke A, Brettner F, Staudinger T, Joannidis M, Verbrugge S
  et al (2016) The feasibility and safety of extracorporeal carbon dioxide removal to avoid intubation in patients with COPD unresponsive
  to noninvasive ventilation for acute hypercapnic respiratory failure
  (ECLAIR study): multicentre case—control study. Intensive Care Med
  42(9):1437—1444
- Del Sorbo L, Fan E, Nava S, Ranieri VM (2016) ECCO2R in COPD exacerbation only for the right patients and with the right strategy. Intensive Care Med 42(11):1830–1831
- Diehl J-L, Piquilloud L, Richard J-CM, Mancebo J, Mercat A (2016) Effects
  of extracorporeal carbon dioxide removal on work of breathing in
  patients with chronic obstructive pulmonary disease. Intensive Care Med
  42(5):951–952
- Gattinoni L, Kolobow T, Tomlinson T, White D, Pierce J (1978) Control of intermittent positive pressure breathing (IPPB) by extracorporeal removal of carbon dioxide. Br J Anaesth 50(8):753–758